Navigation Links
Multimodal Treatment of Peritoneal Metastases Offers Hope for Many Patients With Colorectal Cancer
Date:11/1/2012

BERLIN, November 1, 2012 /PRNewswire/ --

8th World Congress on Peritoneal Surface Malignancies

At the 8th World Congress on Peritoneal Surface Malignancies held from October 30 to November 2 in Berlin, Germany, a paradigm shift was emphasized that offers hope to numerous cancer patients worldwide. So far patients with peritoneal metastases of solid tumors in the abdominal region were considered not to be candidates for curative treatment. These patients had an extremely poor prognosis and were treated solely with systemic chemotherapy within the framework of "best supportive care."

At the international congress definitive data was presented sharing that multimodal treatment of peritoneal metastases of colorectal cancer can be a promising approach and is associated with a five-year survival of up to 30-50%. Dr. Paul Sugarbaker (Washington, DC, USA), surgeon and congress president, is considered a pioneer of this approach which uses a combination of cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC) and subsequent systemic chemotherapy. With HIPEC the chemotherapeutic agent is distributed in the abdominal region at 42°C for about 60 to 90 minutes. "The residual tumor tissue is exposed to a multiple of the normal concentration of the cytotoxic agent that is administered during conventional chemotherapy," explained Sugarbaker. "This is why the method is successful. In selected patients it can double the survival time - and should therefore be considered as a therapeutic option within an individualized treatment approach".

The aspect of individualized treatment is important, because the method is suitable only for patients with isolated and limited peritoneal carcinomatosis without metastases outside the abdomen. "However, this group constitutes up to 15% of all patients with colorectal cancer after all," pointed out Dr. Prof. Pompiliu Piso (Regensburg, Germany), co-president of the congress. "In simple terms this means that in Germany, for example, where there are 70,000 new cases of colon cancer each year, the prognosis of around 10,000 patients could be substantially improved by the use of this method."

Further information

http://www.peritonealconference2012.com

http://www.dgav.de

Press contact
Dr. Bettina Albers
albers@albersconcept.de
Tel. + 49-174-2165629


'/>"/>
SOURCE 8th World Congress on Peritoneal Surface Malignancies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ViThera Novel Approach Using Probiotics to Deliver Elafin Shows Promise as a Future Inflammatory Bowel Disease (IBD) Treatment
2. Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
3. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
4. Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia
5. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
6. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
7. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
8. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
9. CTBE (Brazil) to Acquire Equipment for Biomass Pretreatment Research
10. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
11. Elusys Awarded Additional $50.2 Million Under An Exisiting U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... Ellen Matloff, president and CEO of My ... a 2017 Women of Innovation® finalist. Matloff will be among several women to ... dinner recognizes women accomplished in science, technology, engineering and math (STEM), along with ...
(Date:3/23/2017)... 23, 2017 According to a report by ... market is fragmented due to the presence of a large pool of ... Thermo Fisher , and Sigma-Aldrich, compete with each other in this ... held more than 76% of this market in 2016.  ... As of now, a large ...
(Date:3/23/2017)... Orleans, La. (PRWEB) , ... March 23, 2017 ... ... real-time, industrial monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd ... APMT customer applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career ...
(Date:3/22/2017)... , March 22, 2017  Ascendis Pharma ... its innovative TransCon technology to address significant unmet ... results for the full year ended December 31, ... year for our company as we broadened our ... leading, integrated rare disease company with an initial ...
Breaking Biology Technology:
(Date:2/28/2017)... 2017 News solutions for biometrics, bag drop ... ... 14 to 16 March, Materna will present its complete end-to-end ... travel is a real benefit for passengers. To accelerate the ... passenger touch point solutions to take passengers through the complete ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):